Halozyme Therapeutics, Inc. (HALO)
67.30
-0.40
(-0.59%)
USD |
NASDAQ |
Dec 31, 16:00
67.17
-0.13
(-0.19%)
After-Hours: 20:00
Halozyme Therapeutics Research and Development Expense (TTM): 70.03M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 15.77B |
| Merck & Co., Inc. | 14.26B |
| AIM ImmunoTech, Inc. | 3.826M |
| Bristol Myers Squibb Co. | 9.719B |
| Protalix Biotherapeutics, Inc. | 18.06M |